Breadcrumb Home News News archive A news archive from Sobi in North America News archive A news archive from Sobi in North America Data presented at ASH support emapalumab as an innovative, targeted therapeutic option for primary HLH 12/04/2018 - 01:30 FDA Approves Gamifant® (emapalumab-lzsg), the First and Only Treatment Indicated for Primary Hemophagocytic Lymphohistiocytosis (HLH) Sobi, an international biopharmaceutical company dedicated to rare diseases, and Novimmune SA, a Swiss biotech company, today announced that the U.S. Food and Drug Administration (FDA) has approved Gamifant® (emapalumab-lzsg), an interferon gamma (IFNγ) blocking antibody for the treatment of pediatric (newborn and older) and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy... 11/20/2018 - 15:12 Sobi™ to acquire Synagis® US rights from AstraZeneca - creates a platform for global growth 11/13/2018 - 02:00 Load More
Data presented at ASH support emapalumab as an innovative, targeted therapeutic option for primary HLH 12/04/2018 - 01:30
FDA Approves Gamifant® (emapalumab-lzsg), the First and Only Treatment Indicated for Primary Hemophagocytic Lymphohistiocytosis (HLH) Sobi, an international biopharmaceutical company dedicated to rare diseases, and Novimmune SA, a Swiss biotech company, today announced that the U.S. Food and Drug Administration (FDA) has approved Gamifant® (emapalumab-lzsg), an interferon gamma (IFNγ) blocking antibody for the treatment of pediatric (newborn and older) and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy... 11/20/2018 - 15:12
Sobi™ to acquire Synagis® US rights from AstraZeneca - creates a platform for global growth 11/13/2018 - 02:00